This site is intended for healthcare professionals

Trodelvy demonstrates superior outcomes to standard of care in second-line treatment of metastatic triple-negative breast cancer in phase III ASCENT study- Gilead Sciences

Read time: 1 mins
Last updated:28th Jun 2021
Published:6th Jun 2021
Gilead Sciences, Inc. announced new data from the Phase III ASCENT study evaluating Trodelvy (sacituzumab govitecan-hziy) in relapsed or refractory metastatic triple-negative breast cancer (TNBC).
Condition: Breast Cancer Triple Neg
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest